These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 16322287)

  • 1. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
    Haura EB; Zheng Z; Song L; Cantor A; Bepler G
    Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray.
    Kim HS; Park YH; Lee J; Ahn JS; Kim J; Shim YM; Kim JH; Park K; Han J; Ahn MJ
    Cancer; 2010 Feb; 116(3):676-85. PubMed ID: 20052735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
    Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY
    Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer.
    Cortas T; Eisenberg R; Fu P; Kern J; Patrick L; Dowlati A
    Lung Cancer; 2007 Mar; 55(3):349-55. PubMed ID: 17161498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
    Kobayashi S; Shimamura T; Monti S; Steidl U; Hetherington CJ; Lowell AM; Golub T; Meyerson M; Tenen DG; Shapiro GI; Halmos B
    Cancer Res; 2006 Dec; 66(23):11389-98. PubMed ID: 17145885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.
    Alvarez JV; Greulich H; Sellers WR; Meyerson M; Frank DA
    Cancer Res; 2006 Mar; 66(6):3162-8. PubMed ID: 16540667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.
    Loprevite M; Tiseo M; Chiaramondia M; Capelletti M; Bozzetti C; Bortesi B; Naldi N; Nizzoli R; Dadati P; Kunkl A; Zennaro D; Lagrasta C; Campanini N; Spiritelli E; Camisa R; Grossi F; Rindi G; Franciosi V; Ardizzoni A
    Clin Cancer Res; 2007 Nov; 13(21):6518-26. PubMed ID: 17975165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.
    Song L; Morris M; Bagui T; Lee FY; Jove R; Haura EB
    Cancer Res; 2006 Jun; 66(11):5542-8. PubMed ID: 16740687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
    Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM
    Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
    Bell DW; Lynch TJ; Haserlat SM; Harris PL; Okimoto RA; Brannigan BW; Sgroi DC; Muir B; Riemenschneider MJ; Iacona RB; Krebs AD; Johnson DH; Giaccone G; Herbst RS; Manegold C; Fukuoka M; Kris MG; Baselga J; Ochs JS; Haber DA
    J Clin Oncol; 2005 Nov; 23(31):8081-92. PubMed ID: 16204011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells.
    Chiu HC; Chou DL; Huang CT; Lin WH; Lien TW; Yen KJ; Hsu JT
    Biochem Pharmacol; 2011 Jun; 81(11):1263-70. PubMed ID: 21406185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer.
    Hyogotani A; Ito K; Yoshida K; Izumi H; Kohno K; Amano J
    Clin Lung Cancer; 2012 Sep; 13(5):375-84. PubMed ID: 22284440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
    Han SW; Kim TY; Hwang PG; Jeong S; Kim J; Choi IS; Oh DY; Kim JH; Kim DW; Chung DH; Im SA; Kim YT; Lee JS; Heo DS; Bang YJ; Kim NK
    J Clin Oncol; 2005 Apr; 23(11):2493-501. PubMed ID: 15710947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy.
    Leung EL; Tam IY; Tin VP; Chua DT; Sihoe AD; Cheng LC; Ho JC; Chung LP; Wong MP
    Mol Cancer Res; 2009 Jun; 7(6):923-32. PubMed ID: 19491201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
    Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
    Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
    Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F
    Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
    Cappuzzo F; Magrini E; Ceresoli GL; Bartolini S; Rossi E; Ludovini V; Gregorc V; Ligorio C; Cancellieri A; Damiani S; Spreafico A; Paties CT; Lombardo L; Calandri C; Bellezza G; Tonato M; Crinò L
    J Natl Cancer Inst; 2004 Aug; 96(15):1133-41. PubMed ID: 15292385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer.
    Hosokawa S; Toyooka S; Fujiwara Y; Tokumo M; Soh J; Takigawa N; Hotta K; Yoshino T; Date H; Tanimoto M; Kiura K
    Lung Cancer; 2009 Oct; 66(1):107-13. PubMed ID: 19185949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.
    Dalwadi H; Krysan K; Heuze-Vourc'h N; Dohadwala M; Elashoff D; Sharma S; Cacalano N; Lichtenstein A; Dubinett S
    Clin Cancer Res; 2005 Nov; 11(21):7674-82. PubMed ID: 16278387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.